Table 2.

Differences in total and patient out-of-pocket costs for 30-day supply of PARP inhibitor among ovarian cancer patients based on insurance characteristics

	n (%)	Total cost (median)	Total cost (IQR)	p-value	Patient out-of-pocket cost (median)	Patient out-of-pocket cost (IQR)	p-value
Marketscan cohort (n=570) a
High deductible health plan	35 (6.1)	$13,875	$13,307-$14,839	0.01	$0	$0-$588	0.87
No high deductible health plan	535 (93.9)	$13,315	$11,948-14,237		$45	$0-$121
SEER-Medicare Part D cohort (n=209) b
Dual Medicaid-eligibility prescription coveragec	50 (23.9)	$12,663	$12,450-$13,227	0.57	$1	$0-$2	<0.01
No dual Medicaid-eligibility prescription coverage	159 (76.1)	$12,860	$11,470-$13,157		$911	$44-$1,513
SEER-Medicare Part D cohort (n=159) c
Any PARP inhibitor prescription in catastrophic phase	99 (62.3)	$12,812	$11,209-$13,101	0.25	$1,021	$637-$1,438	0.19
No PARP inhibitor prescription in catastrophic phase	60 (37.7)	$12,862	$12,104-$13,376		$84	$23-$2,733

IQR=interquartile range

^aPatients with high-deductible plan in some months during use of PARP inhibitor and patients with missing insurance type were excluded.

^bPatients with Medicaid supplemental in some months during use of PARP inhibitor were excluded.

^cOnly one patient was a Low-Income Subsidy Medicare beneficiary.

^dPatients with any Medicaid supplemental insurance were excluded.